Profiling of mucormycosis in district of central rural India during COVID-19 pandemic: a record-based study

Authors

  • Mohnish Y. Giri Department of Community Medicine, MGIMS Sevagram, Wardha, Maharashtra, India
  • Dharmpal G. Dambhare Department of Community Medicine, MGIMS Sevagram, Wardha, Maharashtra, India
  • Vinit Jhalke District Epidemiologist, Wardha District, Maharashtra, India
  • R. Naveen Shyam Sundar Department of Community Medicine, MGIMS Sevagram, Wardha, Maharashtra, India
  • Devyani Vanjari Department of Community Medicine, MGIMS Sevagram, Wardha, Maharashtra, India

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20230221

Keywords:

Mucormycosis, Record based study, COVID-19

Abstract

Background: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with a wide range of opportunistic bacterial and fungal infections. Several cases of Mucormycosis in people with COVID-19 have been increasingly reported world-wide, in particular from India. The primary reason that appears to be facilitating Mucorales spores to germinate in people with COVID-19 is an ideal environment of low oxygen (hypoxia), high glucose (diabetes, new onset hyperglycemia, steroid-induced hyperglycemia).

Methods: Secondary data was obtained from District health office Wardha. We took Mucormycosis related data for May 2021 to August 2021. A Secondary data analysis was done as an age wise distribution, Sex wise distribution, classification of Mucormycosis and case load in Wardha district.

Results: Total cases (overall) was about 132. 91% cases are totally recovered. In overall cases, 106 males and 26 females were affected due to Mucormycosis. Out of 132 cases, 128 cases were of Rhino cerebral type of Mucormycosis. 48% cases of Mucormycosis were from 45 to 60 years old patients.127 cases of Mucormycosis were related with COVID history and only 5 cases of Mucormycosis were not related with COVID history. 53% cases were needed oxygen support prior onset of case.

Conclusions: A multidisciplinary strategy should incorporate early diagnosis, antifungal therapy, any necessary surgical consultation and treatment, as well as reversal of the underlying illness. Identification of individuals at risk, strict glycaemic control and avoidance of unnecessary corticosteroid in non-severe COVID-19 cases (normal oxygen saturation on room air) can help in preventing this complication.

Metrics

Metrics Loading ...

References

Kubin CJ, McConville TH, Dietz D, Zucker J, May M, Nelson B, et al. Characterization of bacterial and fungal infections in hospitalized patients with coronavirus disease 2019 and factors associated with health care-associated infections. Open Forum Infect Dis. 2021;8(6):1-10.

Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr Clin Res Rev. 2021;15(4):102146.

Bala K, Chander J, Handa U, Punia RS, Attri AK. A prospective study of mucormycosis in north India: Experience from a tertiary care hospital. Med Mycol. 2015;53(3):248-57.

Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019;5(1):23-9.

Lenus S, Ramadevi M, Muneeswar Reddy T, Jaya Bhaskar C, Bhavana A. A Study to Identify the Risk Factors and their Relationship with Mucormycosis Severity in COVID Pneumonia. Eur J Clin Med. 2022;3(1):37-40.

Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-69.

Alekseyev K, Didenko L, Chaudhry B. Rhinocerebral Mucormycosis and COVID-19 Pneumonia. J Med Cases. 2021;12(3):85-9.

Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. multistate point-prevalence survey of health care–associated infections. N Engl J Med. 2014;370(13):1198-208.

Sen M, Lahane S, Lahane TP, Parekh R. Mucor in a Viral land: a tale of two pathogens mrittika. Indian J Ophthal. 2021;69(1):244-52.

John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe covid-19 converge: The perfect storm for mucormycosis. J Fungi. 2021;7(4):32-8.

Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: We should be prepared. J Mycol Med. 2020;30(2):43-9.

Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12(9):10-4.

Sarkar S, Gokhale T, Choudhury SS DA. COVID-19 and orbital mucormycosis Dear. 1 Indian J Ophthal. 2021;69(4):1002-4.

Chander J, Kaur M, Singla N, Punia RPS, Singhal SK, Attri AK, et al. Mucormycosis: Battle with the deadly enemy over a five-year period in India. J Fungi. 2018;4(2):36-9.

Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-53.

Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26(7):e9-e15.

Downloads

Published

2023-01-27

How to Cite

Giri, M. Y., Dambhare, D. G., Jhalke, V., Sundar, R. N. S., & Vanjari, D. (2023). Profiling of mucormycosis in district of central rural India during COVID-19 pandemic: a record-based study . International Journal Of Community Medicine And Public Health, 10(2), 682–686. https://doi.org/10.18203/2394-6040.ijcmph20230221

Issue

Section

Original Research Articles